Workflow
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
AXDXAccelerate Diagnostics(AXDX) ZACKS·2024-11-07 23:41

Earnings Performance - Accelerate Diagnostics reported a quarterly loss of 059pershare,missingtheZacksConsensusEstimateofalossof0 59 per share, missing the Zacks Consensus Estimate of a loss of 0 47 This represents a 25 53% earnings surprise [1][2] - The company's loss per share improved from 092ayearago,indicatingareductioninlosses[1]−Overthelastfourquarters,thecompanyhassurpassedconsensusEPSestimatesonlyonce[2]RevenuePerformance−AccelerateDiagnosticspostedrevenuesof0 92 a year ago, indicating a reduction in losses [1] - Over the last four quarters, the company has surpassed consensus EPS estimates only once [2] Revenue Performance - Accelerate Diagnostics posted revenues of 2 98 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0 83% [3] - This compares to year-ago revenues of 33million,showingadecline[3]−Thecompanyhasnotbeenabletobeatconsensusrevenueestimatesoverthelastfourquarters[3]StockPerformance−AccelerateDiagnosticsshareshavelostabout4923 3 million, showing a decline [3] - The company has not been able to beat consensus revenue estimates over the last four quarters [3] Stock Performance - Accelerate Diagnostics shares have lost about 49 2% since the beginning of the year, significantly underperforming the S&P 500's gain of 24 3% [4] - The stock's immediate price movement will depend on management's commentary on the earnings call [4] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -0 46 on 31millioninrevenues[8]−Forthecurrentfiscalyear,theconsensusEPSestimateis−3 1 million in revenues [8] - For the current fiscal year, the consensus EPS estimate is -2 14 on 12millioninrevenues[8]−TheestimaterevisionstrendforAccelerateDiagnosticsismixed,translatingintoaZacksRank3(Hold)[7]IndustryContext−AccelerateDiagnosticsbelongstotheZacksMedical−Instrumentsindustry,whichiscurrentlyinthetop2512 million in revenues [8] - The estimate revisions trend for Accelerate Diagnostics is mixed, translating into a Zacks Rank 3 (Hold) [7] Industry Context - Accelerate Diagnostics belongs to the Zacks Medical - Instruments industry, which is currently in the top 25% of the 250 plus Zacks industries [9] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [9] Peer Comparison - KORU Medical Systems Inc (KRMD), another stock in the same industry, is expected to post a quarterly loss of 0 03 per share, unchanged from the year-ago quarter [10] - KORU Medical Systems Inc's revenues are expected to be $7 66 million, up 9 4% from the year-ago quarter [11]